Clinical outcomes after CPX‐351 in patients with high‐risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry

Autor: Teresa Bernal, Ainhoa Fernández Moreno, Almudena de LaIglesia, Celina Benavente, Ana García‐Noblejas, Daniel García Belmonte, Rosalía Riaza, Olga Salamero, Maria Angeles Foncillas, Alicia Roldán, Víctor Noriega Concepción, Laura Llorente González, Juan Miguel Bergua Burgués, Soraya Lorente de Uña, Gabriela Rodríguez‐Macías, Adolfo de la Fuente Burguera, Maria José García Pérez, Jose Luis López‐Lorenzo, Pilar Martínez, Concepción Aláez, Marta Callejas, Carmen Martínez‐Chamorro, José Rifón Roca, Lourdes Amador Barciela, Armando V. Mena Durán, Karoll Gómez Correcha, Esperanza Lavilla Rubira, María Luz Amigo, Ferran Vall‐llovera, Ana Garrido, María García‐Fortes, Dunia de Miguel Llorente, Anastasia Aules Leonardo, Carlos Cervero, Rosa Coll Jordá, Manuel M. Pérez‐Encinas, Marta Polo Zarzuela, Angela Figuera, Guillermo Rad, David Martínez‐Cuadrón, Pau Montesinos
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: Cancer Medicine, Vol 12, Iss 14, Pp 14892-14901 (2023)
Druh dokumentu: article
ISSN: 2045-7634
DOI: 10.1002/cam4.6120
Popis: Abstract Background CPX‐351 is approved for the treatment of therapy related acute myeloid leukemia (t‐AML) and AML with myelodysplastic related changes (MRC‐AML). The benefits of this treatment over standard chemotherapy has not been addressed in well matched cohorts of real‐life patients. Methods Retrospective analysis of AML patients treated with CPX‐351 as per routine practice. A propensity score matching (PSM) was used to compare their main outcomes with those observed in a matched cohort among 765 historical patients receiving intensive chemotherapy (IC), all of them reported to the PETHEMA epidemiologic registry. Results Median age of 79 patients treated with CPX‐351 was 67 years old (interquartile range 62–71), 53 were MRC‐AML. The complete remission (CR) rate or CR without recovery (CRi) after 1 or 2 cycles of CPX‐351 was 52%, 60‐days mortality 18%, measurable residual disease
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje